Ren Huhu, Chen Jian, Wu Zhiqun, Li Chen
Hong Hui Hospital, Xi'an Jiaotong University, Xi'an, China.
Front Oncol. 2025 Apr 16;15:1566865. doi: 10.3389/fonc.2025.1566865. eCollection 2025.
Hepatocellular carcinoma (HCC) is a major cancer challenge worldwide. Combination therapy using transcatheter arterial chemoembolization (TACE) and percutaneous ablation offers potential for improved outcomes.
To evaluate the efficacy and liver function preservation in HCC patients treated with combined TACE and percutaneous ablation, identifying key prognostic factors.
This longitudinal study included 200 HCC patients. Factors analyzed included tumor characteristics, liver function tests, and serologic markers. Statistical analyses determined associations with treatment outcomes and survival.
Smaller tumors (≤5.0 cm) and lower AFP levels (<200 ng/mL) were associated with higher treatment efficacy, with an objective response rate of 67.3% for lower AFP levels versus 42.3% for higher levels. Liver function was better preserved in patients with lower AFP levels (78.2% vs. 57.7%). Tumor size and liver stiffness significantly influenced survival and liver function outcomes.
The combination of TACE and percutaneous ablation enhances outcomes in HCC, guided by specific prognostic markers. This supports the need for personalized approaches in HCC treatment and further research into combination therapies.
肝细胞癌（HCC）是全球主要的癌症挑战。经导管动脉化疗栓塞术（TACE）联合经皮消融的联合治疗为改善治疗效果提供了可能。
评估接受TACE与经皮消融联合治疗的HCC患者的疗效及肝功能保留情况，确定关键预后因素。
这项纵向研究纳入了200例HCC患者。分析的因素包括肿瘤特征、肝功能检查和血清学标志物。统计分析确定与治疗结果和生存的关联。
较小的肿瘤（≤5.0 cm）和较低的甲胎蛋白（AFP）水平（<200 ng/mL）与较高的治疗疗效相关，AFP水平较低者的客观缓解率为67.3%，而AFP水平较高者为42.3%。AFP水平较低的患者肝功能保留情况更好（78.2%对57.7%）。肿瘤大小和肝脏硬度显著影响生存和肝功能结果。
在特定预后标志物的指导下，TACE与经皮消融联合可改善HCC的治疗效果。这支持了HCC治疗中个性化方法的必要性以及对联合治疗的进一步研究。
